AdvisorShares Investments LLC Makes New $742,000 Investment in Supernus Pharmaceuticals, Inc. $SUPN

AdvisorShares Investments LLC bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 3rd quarter, HoldingsChannel reports. The fund bought 15,525 shares of the specialty pharmaceutical company’s stock, valued at approximately $742,000.

Several other large investors have also recently bought and sold shares of SUPN. Royal Bank of Canada boosted its holdings in shares of Supernus Pharmaceuticals by 68.1% in the first quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after acquiring an additional 4,729 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 35.2% during the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after acquiring an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Supernus Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after purchasing an additional 1,297 shares in the last quarter. Millennium Management LLC increased its position in shares of Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares in the last quarter. Finally, Empowered Funds LLC grew its position in Supernus Pharmaceuticals by 16.0% during the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares in the last quarter.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $781,153.36. The trade was a 56.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the transaction, the vice president owned 14,508 shares in the company, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. TD Cowen upped their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Zacks Research cut Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Finally, Bank of America started coverage on Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $61.60.

Supernus Pharmaceuticals Stock Up 4.6%

Shares of Supernus Pharmaceuticals stock opened at $51.65 on Friday. The stock has a market capitalization of $2.96 billion, a P/E ratio of -151.91, a price-to-earnings-growth ratio of 0.65 and a beta of 0.71. The company has a 50-day simple moving average of $49.12 and a 200 day simple moving average of $46.76. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $57.65.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.